TR200100666T2 - Hemen yayılan tablet. - Google Patents

Hemen yayılan tablet.

Info

Publication number
TR200100666T2
TR200100666T2 TR2001/00666T TR200100666T TR200100666T2 TR 200100666 T2 TR200100666 T2 TR 200100666T2 TR 2001/00666 T TR2001/00666 T TR 2001/00666T TR 200100666 T TR200100666 T TR 200100666T TR 200100666 T2 TR200100666 T2 TR 200100666T2
Authority
TR
Turkey
Prior art keywords
tablet
filler
weight
immediate
spreading
Prior art date
Application number
TR2001/00666T
Other languages
English (en)
Inventor
Forsman Sigbrit
Karlsson Christer
Karlsson Magnus
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of TR200100666T2 publication Critical patent/TR200100666T2/tr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/397—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having four-membered rings, e.g. azetidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Inorganic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

pH 'ye bagli çözülmeye sahip düsük moleküler agirlik trombin inhibitörü için kati formda yeni bir oral hemen yayilan (IR) formülasyon olup, formülasyonun kendisinin % 35 agirlik/agirlik'tan daha yüksek oranda ve dagilan özelliklere sahip bir dolgu maddesi veya bir dolgu maddesi kombinasyonuna sahip olmasi ile karakterize olmaktadir.
TR2001/00666T 1998-09-03 1999-08-27 Hemen yayılan tablet. TR200100666T2 (tr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
SE9802973A SE9802973D0 (sv) 1998-09-03 1998-09-03 Immediate release tablet

Publications (1)

Publication Number Publication Date
TR200100666T2 true TR200100666T2 (tr) 2001-08-21

Family

ID=20412467

Family Applications (2)

Application Number Title Priority Date Filing Date
TR2001/00666T TR200100666T2 (tr) 1998-09-03 1999-08-27 Hemen yayılan tablet.
TR2005/02188T TR200502188T2 (tr) 1998-09-03 1999-08-27 Hemen yayılan tablet

Family Applications After (1)

Application Number Title Priority Date Filing Date
TR2005/02188T TR200502188T2 (tr) 1998-09-03 1999-08-27 Hemen yayılan tablet

Country Status (32)

Country Link
US (3) US6521253B1 (tr)
EP (2) EP1527787A1 (tr)
JP (2) JP4026678B2 (tr)
KR (2) KR20060097071A (tr)
CN (3) CN1951371A (tr)
AR (1) AR029313A1 (tr)
AT (1) ATE286385T1 (tr)
AU (1) AU746129B2 (tr)
BR (1) BR9913400A (tr)
CA (1) CA2341397C (tr)
CZ (1) CZ300830B6 (tr)
DE (1) DE69923074T2 (tr)
EE (1) EE200100134A (tr)
ES (1) ES2234296T3 (tr)
HU (1) HU227278B1 (tr)
ID (1) ID29629A (tr)
IL (2) IL141439A0 (tr)
IS (1) IS5869A (tr)
MY (1) MY124359A (tr)
NO (1) NO20011085L (tr)
NZ (2) NZ539749A (tr)
PL (1) PL195603B1 (tr)
PT (1) PT1109537E (tr)
RU (2) RU2252751C2 (tr)
SA (1) SA99200683B1 (tr)
SE (1) SE9802973D0 (tr)
SK (1) SK285507B6 (tr)
TR (2) TR200100666T2 (tr)
TW (1) TW561056B (tr)
UA (1) UA75567C2 (tr)
WO (1) WO2000013671A1 (tr)
ZA (1) ZA200101762B (tr)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE9802973D0 (sv) * 1998-09-03 1998-09-03 Astra Ab Immediate release tablet
SE9904377D0 (sv) * 1999-12-01 1999-12-01 Astra Pharma Prod Pharmaceutical combinations
CZ20024180A3 (cs) * 2000-06-22 2003-04-16 Novartis Ag Pevné orální farmaceutické kompozice obsahující valsartan
US6462021B1 (en) 2000-11-06 2002-10-08 Astrazeneca Ab Use of low molecular weight thrombin inhibitor
AR035216A1 (es) * 2000-12-01 2004-05-05 Astrazeneca Ab Derivados de acido mandelico ,derivados farmaceuticamente aceptables, uso de estos derivados para la fabricacion de medicamentos, metodos de tratamiento ,procesos para la preparacion de estos derivados, y compuestos intermediarios
US7129233B2 (en) 2000-12-01 2006-10-31 Astrazeneca Ab Mandelic acid derivatives and their use as thrombin inhibitors
AR034517A1 (es) * 2001-06-21 2004-02-25 Astrazeneca Ab Formulacion farmaceutica
SE0103369D0 (sv) * 2001-10-09 2001-10-09 Astrazeneca Ab Pharmaceutical formulation
FR2833493B1 (fr) * 2001-12-18 2005-09-23 Ioltechnologie Production Forme galenique solide et soluble pour l'administration occulaire de principes actifs et procede de fabrication d'un insert ophtalmique solide et soluble
EP1569912B1 (en) 2002-12-03 2015-04-29 Pharmacyclics, Inc. 2-(2-hydroxybiphenyl-3-yl)-1h-benzoimidazole-5-carboxamidine derivatives as factor viia inhibitors
US20030181488A1 (en) 2002-03-07 2003-09-25 Boehringer Ingelheim Pharma Gmbh & Co. Kg Administration form for the oral application of 3-[(2-{[4-(hexyloxycarbonylamino-imino-methyl)-phenylamino]-methyl}-1-methyl-1H-benzimidazol-5-carbonyl)-pyridin-2-yl-amino]-propionic acid ethyl ester and the salts thereof
SI1488790T1 (sl) * 2002-03-28 2014-09-30 Teijin Pharma Limited Trden pripravek, ki vsebuje eno samo kristalno a-obliko derivata tiazolkarboksilne kisline
SE0201661D0 (sv) 2002-05-31 2002-05-31 Astrazeneca Ab New salts
SE0201659D0 (sv) 2002-05-31 2002-05-31 Astrazeneca Ab Modified release pharmaceutical formulation
SE0201658D0 (sv) * 2002-05-31 2002-05-31 Astrazeneca Ab Immediate release pharmaceutical formulation
US7781424B2 (en) * 2003-05-27 2010-08-24 Astrazeneca Ab Modified release pharmaceutical formulation
WO2005065662A1 (en) * 2003-12-31 2005-07-21 Actavis Group Hf Solid dosage formulations of galantamine
KR100574554B1 (ko) * 2004-05-28 2006-04-27 한미약품 주식회사 니아신의 경구투여용 서방성 조성물
US8022053B2 (en) * 2004-11-02 2011-09-20 Bayer Schering Pharma Aktiengesellschaft Oral solid dosage forms containing a low dose of estradiol
US7524354B2 (en) * 2005-07-07 2009-04-28 Research Foundation Of State University Of New York Controlled synthesis of highly monodispersed gold nanoparticles
US8980337B2 (en) * 2006-06-29 2015-03-17 Tsumura & Co. Tablet composition containing kampo extract
TW200827336A (en) * 2006-12-06 2008-07-01 Astrazeneca Ab New crystalline forms
DK2118074T3 (en) 2007-02-01 2014-03-10 Resverlogix Corp Compounds for the prevention and treatment of cardiovascular diseases
US20090061000A1 (en) * 2007-08-31 2009-03-05 Astrazeneca Ab Pharmaceutical formulation use 030
DE102008014237A1 (de) * 2008-03-14 2009-09-17 J. Rettenmaier & Söhne Gmbh + Co. Kg Direktverpressbares Tablettierhilfsmittel
CA2755274C (en) * 2009-03-13 2017-02-28 Sahoe Kakuda Tablet and granulated powder containing 6-fluoro-3-hydroxy-2-pyrazinecarboxamide
KR101709492B1 (ko) 2009-03-18 2017-02-23 리스버로직스 코퍼레이션 신규한 소염제
US9757368B2 (en) 2009-04-22 2017-09-12 Resverlogix Corp. Anti-inflammatory agents
RU2640115C2 (ru) 2011-11-01 2017-12-26 Ресверлоджикс Корп. Фармацевтические композиции замещенных хиназолинонов
US10213421B2 (en) 2012-04-04 2019-02-26 Alkahest, Inc. Pharmaceutical formulations comprising CCR3 antagonists
US9073878B2 (en) 2012-11-21 2015-07-07 Zenith Epigenetics Corp. Cyclic amines as bromodomain inhibitors
WO2014080291A2 (en) 2012-11-21 2014-05-30 Rvx Therapeutics Inc. Biaryl derivatives as bromodomain inhibitors
US9271978B2 (en) 2012-12-21 2016-03-01 Zenith Epigenetics Corp. Heterocyclic compounds as bromodomain inhibitors
GB201400034D0 (en) * 2014-01-02 2014-02-19 Astrazeneca Ab Pharmaceutical Compositions comprising AZD9291
US10111885B2 (en) 2015-03-13 2018-10-30 Resverlogix Corp. Compositions and therapeutic methods for the treatment of complement-associated diseases

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1601833A (en) 1978-02-06 1981-11-04 Wellcome Found Antacid formulation
US4517179A (en) * 1983-04-29 1985-05-14 Pennwalt Corporation Rapid dissolving, uniform drug compositions and their preparation
IT1200178B (it) 1986-07-23 1989-01-05 Alfa Farmaceutici Spa Formulazioni galeniche a cessione programmata contenenti farmaci ad attivita' antiflogistica
AR240018A1 (es) * 1987-10-07 1990-01-31 Merrell Pharma Inc Procedimiento para preparar una composicion que comprende derivados de piperidinoalcanol.
US5430023A (en) * 1990-09-28 1995-07-04 Eli Lilly And Company Tripeptide antithrombotic agents
SE9102462D0 (sv) 1991-08-28 1991-08-28 Astra Ab New isosteric peptides
SE9103612D0 (sv) * 1991-12-04 1991-12-04 Astra Ab New peptide derivatives
JPH05213927A (ja) * 1992-02-10 1993-08-24 Torii Yakuhin Kk 新規フランカルボン酸アミジノナフチルエステル誘導体およびその酸付加塩
US5532267A (en) * 1992-02-10 1996-07-02 Torii & Co., Ltd. Amidinonaphthyl furancarboxylate derivatives and acid addition salts therof
US5470955A (en) 1993-02-02 1995-11-28 Dartmouth College Antibodies which specifically bind mcl-1 polypeptide
SE9301916D0 (sv) * 1993-06-03 1993-06-03 Ab Astra New peptides derivatives
US5436229A (en) * 1994-03-04 1995-07-25 Eli Lilly And Company Bisulfite adducts of arginine aldehydes
CA2193681A1 (en) 1994-07-08 1996-01-25 Astra Aktiebolag New oral pharmaceutical formulation containing magnesium salt of omeprazole
US5510369A (en) * 1994-07-22 1996-04-23 Merck & Co., Inc. Pyrrolidine thrombin inhibitors
DE19530575A1 (de) * 1995-08-19 1997-02-20 Gruenenthal Gmbh Schnell zerfallende Arzneiform von Tramadol oder einem Tramadolsalz
US5733578A (en) 1995-11-15 1998-03-31 Edward Mendell Co., Inc. Directly compressible high load acetaminophen formulations
TW430561B (en) 1995-12-20 2001-04-21 Gea Farmaceutisk Fabrik As Rapid release tablet composition comprising tolfenamic acid or a pharmaceutically acceptable salt thereof as active ingredient and a method of preparing such tablet
TW541316B (en) * 1995-12-21 2003-07-11 Astrazeneca Ab Prodrugs of thrombin inhibitors
EP0803251B1 (en) * 1996-04-23 2002-07-17 Janssen Pharmaceutica N.V. Immediate release pH-independent solid dosage form of cisapride
SE9601556D0 (sv) * 1996-04-24 1996-04-24 Astra Ab New pharmaceutical formulation of a thrombin inhibitor for parenteral use
DE19628617A1 (de) * 1996-07-16 1998-01-22 Basf Ag Direkttablettierhilfsmittel
WO1998011896A1 (en) * 1996-09-18 1998-03-26 Merck & Co., Inc. Combination therapy for reducing the risks associated with cardiovascular disease
HRP970493A2 (en) * 1996-09-23 1998-08-31 Wienman E. Phlips Oral delayed immediate release medical formulation and method for preparing the same
SE9603724D0 (sv) * 1996-10-11 1996-10-11 Astra Ab New pharmaceutical parenteral formulation of a thrombin inhibitor
US5798377A (en) * 1996-10-21 1998-08-25 Merck & Co., Inc. Thrombin inhibitors
UA69413C2 (uk) 1998-05-22 2004-09-15 Брістол-Майерс Сквібб Компані Фармацевтична композиція, яка містить серцевину та ентеросолюбільну оболонку, фармацевтична композиція у вигляді сфероїдальних гранул, спосіб одержання сфероїдальних гранул та спосіб одержання фармацевтичної композиції
GB9814215D0 (en) 1998-07-01 1998-09-02 Norton Healthcare Ltd Anti-inflammatory pharmaceutical formulations
CA2239931A1 (en) 1998-07-15 2000-01-15 Bernard Charles Sherman Pharmaceutical tablet comprising norfloxacin
US6368625B1 (en) 1998-08-12 2002-04-09 Cima Labs Inc. Orally disintegrable tablet forming a viscous slurry
SE9802973D0 (sv) * 1998-09-03 1998-09-03 Astra Ab Immediate release tablet
US6602521B1 (en) 1998-09-29 2003-08-05 Impax Pharmaceuticals, Inc. Multiplex drug delivery system suitable for oral administration
JP2002541092A (ja) 1999-04-06 2002-12-03 ファーマクエスト・リミテッド メチルフェニデートのパルス性送達のための薬学的投薬形態
KR100634937B1 (ko) 1999-04-13 2006-10-17 비참 파마슈티컬스 (피티이) 리미티드 신규한 치료 방법

Also Published As

Publication number Publication date
WO2000013671A1 (en) 2000-03-16
TR200502188T2 (tr) 2006-12-21
EP1527787A1 (en) 2005-05-04
KR20060097071A (ko) 2006-09-13
ES2234296T3 (es) 2005-06-16
AR029313A1 (es) 2003-06-25
PL195603B1 (pl) 2007-10-31
BR9913400A (pt) 2001-05-22
CA2341397C (en) 2009-02-03
US20030118644A1 (en) 2003-06-26
EP1109537B1 (en) 2005-01-05
AU5892499A (en) 2000-03-27
PT1109537E (pt) 2005-04-29
UA75567C2 (en) 2006-05-15
HUP0103886A3 (en) 2002-08-28
CN1951371A (zh) 2007-04-25
KR100696350B1 (ko) 2007-03-20
NO20011085L (no) 2001-05-03
HU227278B1 (en) 2011-01-28
DE69923074D1 (de) 2005-02-10
IL141439A0 (en) 2002-03-10
HUP0103886A2 (hu) 2002-04-29
PL346545A1 (en) 2002-02-11
CN1544088A (zh) 2004-11-10
SA99200683B1 (ar) 2006-12-05
ATE286385T1 (de) 2005-01-15
NZ539749A (en) 2006-11-30
US20050208128A1 (en) 2005-09-22
RU2005100986A (ru) 2006-06-20
CA2341397A1 (en) 2000-03-16
CN1315855A (zh) 2001-10-03
SK285507B6 (sk) 2007-03-01
EE200100134A (et) 2002-06-17
DE69923074T2 (de) 2005-12-08
CZ300830B6 (cs) 2009-08-19
SK2812001A3 (en) 2001-09-11
CN1158070C (zh) 2004-07-21
SE9802973D0 (sv) 1998-09-03
AU746129B2 (en) 2002-04-18
EP1109537A1 (en) 2001-06-27
ID29629A (id) 2001-09-06
TW561056B (en) 2003-11-11
IS5869A (is) 2001-02-28
RU2252751C2 (ru) 2005-05-27
NZ509943A (en) 2004-01-30
CZ2001774A3 (cs) 2001-10-17
NO20011085D0 (no) 2001-03-02
JP4026678B2 (ja) 2007-12-26
IL141439A (en) 2006-07-05
JP2007039472A (ja) 2007-02-15
ZA200101762B (en) 2002-06-03
JP2002524412A (ja) 2002-08-06
MY124359A (en) 2006-06-30
KR20010090436A (ko) 2001-10-18
US6521253B1 (en) 2003-02-18
US6875446B2 (en) 2005-04-05

Similar Documents

Publication Publication Date Title
TR200502188T2 (tr) Hemen yayılan tablet
EP0931788A3 (en) Metalloprotease inhibitors
TR200101339T2 (tr) Potasyum kanal modülatörleri olarak 3-yer-alanlı-4-arilkinolin-2-on türevleri, 3,4-okzadiazolon türevleri
TR200002953T2 (tr) İki halkalı hidroksamik asit türevleri
GEP20053614B (en) Compositions for Oral Administration Containing Opioid Agonist
BG105369A (en) Arylpiperazines and their use as metalloproteinase inhibiting agent (mmp
TR200101261T2 (tr) Uzun süreli salınımlı ranolazin formülasyonları.
TR199902655A2 (tr) Kükürt-fonksiyonel poliorganosiloksanlar
CY1116023T1 (el) Μορφες φαρμακευτικης δοσολογιας παρατεταμενης απελευθερωσης με περιγραμματα διαλυτοποιησης ελαχιστοποιημενης εξαρτησης απο το ph
TR200003581T2 (tr) Yeni 3-aril-2-hidroksipropiyonik asit türevi (I)
DE69830715D1 (de) Wasserbeständige maskara-zusammensetzung
AU2003303458A1 (en) Ampholytic copolymer and use thereof
BR0010215A (pt) Derivados de indolina como antagonistas de progesterona
BR0116831A (pt) Composição oral e seu uso
AU2963400A (en) Improved controlled release compositions and method
TR200400187T2 (tr) Yeni oral formülasyon.
AU2003227532A1 (en) Mononucleotide repeats microsatellite markers for detecting microsatellite instability.
MXPA02012659A (es) Derivados de pirazindiona condensados.
AU2001237618A1 (en) Copolymer
PE20001060A1 (es) Nueva composicion oral compactada que comprende derivados de catecol
HRPK20040372B3 (en) Crystalline sodium salt of telmisartan and the use of the same as an angiotensin antagonist
AP2003002716A0 (en) Medicinal compositions containing propenone derivatives.
DE60005031D1 (de) Partikel mit kontrollierter freisetzungsrate
BG101401A (bg) Състави за орално приложение с удължено освобождаване на цисаприд
UA74363C2 (uk) Глиниста суміш, здатна утворювати вологостійкий гель